Abstract
Venous disorders are among the most common conditions in the Western world. To understand the various venous disorders, it is important to understand the normal anatomy. Venous disorders can be divided into acute and chronic.
Acute venous disorders are entirely thrombotic. The physiology of the acute thrombotic events can be ascribed to Virchow’s triad: hypercoagulability, hemodynamic changes (venous stasis), and endothelial injury/dysfunction. Examples are superficial thrombophlebitis, acute deep venous thrombosis, acute axillary-subclavian venous thrombosis, and portal vein system thrombosis. Novel therapeutic strategies for lower extremity acute vein thrombosis, such as catheter-directed thrombolysis, may be associated with a reduction of post-thrombotic syndrome risk.
Chronic venous disorders are dominated by reflux through incompetent valves. It is thought that the development of all the clinical manifestations of chronic venous insufficiency (CVI) can be ascribed to a blood flow-driven inflammatory process. All the clinical manifestations of primary and secondary CVI may be conducted by this basic pathogenic mechanism. Telangiectasias and reticular varicosities are to be considered miniature varicose veins. Skin changes, such as atrophie blanche, lipodermatosclerosis, and venous ulcers, are to be considered advanced manifestations and therefore part of the pathologic spectrum of CVI.
Thermal and chemical ablations for axial reflux have almost completely replaced high ligation and stripping of the great saphenous vein and short saphenous vein. In patients with post-thrombotic syndrome, iliac vein recanalization, angioplasty, and stenting have been shown to aid time to ulcer healing.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bergan JJ, Sparks S. Overview of venous disorders. In: AbuRahma AF, Bergan JJ, editors. Non invasive vascular diagnosis. London: Springer; 2000.
Caggiati A, Bergan JJ, Gloviczki P, Jantet G, Wendall-Smith CP, Partsch H, et al. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. J Vasc Surg. 2002;36(2):416–22.
Caggiati A, Bergan JJ, Gloviczki P, Eklof B, Allegra C, Partsch H. Nomenclature of the veins of the lower limb: extensions, refinements, and clinical application. J Vasc Surg. 2005;41(4):719–24.
Gloviczki P, Moses G. D.a.A.o.t.v.s. In: Gloviczki P, Dalsing MC, editors. Handbook of venous disorders: guidelines of the American Venous Forum. 3rd ed. London: Hodder Arnold; 2009. P. xxiii, 744.
Litzendorf ME, Satiani B. Superficial venous thrombosis: disease progression and evolving treatment approaches. Vasc Health Risk Manag. 2011;7:569–75.
Maddox RP, Seupaul RA. What is the most effective treatment of superficial thrombophlebitis? Ann Emerg Med. 2016;67:671–2.
Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010;38(Supp 4):S495–501.
Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32–67.
Liew A, Douketis J. Catheter-directed thrombolysis for extensive iliofemoral deep vein thrombosis: review of literature and ongoing trials. Expert Rev Cardiovasc Ther. 2016;14(2):189–200.
Neglen P, Raju S. Intravascular ultrasound scan evaluation of the obstructed vein. J Vasc Surg. 2002;35(4):694–700.
Popuri RK, Vedantham S. The role of thrombolysis in the clinical management of deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2011;31(3):479–84.
Thompson RW. Challenges in the treatment of thoracic outlet syndrome. Tex Heart Inst J. 2012;39(6):842–3.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.
Norris CS, Greenfield LJ, Hermann JB. Free-floating iliofemoral thrombus. A risk of pulmonary embolism. Arch Surg. 1985;120:806–8.
Kosir MA, Kozol RA, Perales A, McGee K, Beleski K, Lange P, et al. Is DVT prophylaxis overemphasized? A randomized prospective study. J Surg Res. 1996;60(2):289–92.
Kline JA, Courtney DM, Kabrhel C, Moore CL, Smithline HA, Plewa MC, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost. 2008;6(5):772–80.
Ponziani FR, Zocco MA, Campanale C, Rinninella E, Tortora A, Di Maurizio L, et al. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol. 2010;16(2):143–55.
Hollingshead M, Burke CT, Mauro MA, Weeks SM, Dixon RG, Jaques PF. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol. 2005;16(5):651–61.
Rosen MP, Sheiman R. Transhepatic mechanical thrombectomy followed by infusion of TPA into the superior mesenteric artery to treat acute mesenteric vein thrombosis. J Vasc Interv Radiol. 2000;11(2 Pt 1):195–8.
Ludwig DJ, Hauptmann E, Rosoff L Jr, Neuzil D. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery. J Vasc Surg. 1999;30(3):551–4.
Bergan JJ, Pascarella L, Schmid-Schonbein GW. Pathogenesis of primary chronic venous disease: insights from animal models of venous hypertension. J Vasc Surg. 2008;47(1):183–92.
Eklof B, Rutherford RB, Bergan JJ, Carpentier PH, Gloviczki P, Kistner RL, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40(6):1248–52.
Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Gloviczki ML, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53(5 Suppl):2S–48S.
Nesbitt C, Bedenis R, Bhattacharya V, Stansby G. Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus open surgery for great saphenous vein varices. Cochrane Database Syst Rev. 2014;7:CD005624.
Harlander-Locke M, Lawrence P, Jimenez JC, Rigberg D, DeRubertis B, Gelabert H. Combined treatment with compression therapy and ablation of incompetent superficial and perforating veins reduces ulcer recurrence in patients with CEAP 5 venous disease. J Vasc Surg. 2012;55(2):446–50.
O’Donnell TF Jr, Passman MA, Marston WA, Ennis WJ, Dalsing M, Kistner RL, et al. Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery (R) and the American Venous Forum. J Vasc Surg. 2014;60(2 Suppl):3S–59S.
Alhalbouni S, Hingorani A, Shiferson A, Gopal K, Jung D, Novak D, et al. Iliac-femoral venous stenting for lower extremity venous stasis symptoms. Ann Vasc Surg. 2012;26(2):185–9.
Seager MJ, Busuttil A, Dharmarajah B, Davies AH. Editor’s choice—a systematic review of endovenous stenting in chronic venous disease secondary to iliac vein obstruction. Eur J Vasc Endovasc Surg. 2016;51(1):100–20.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Review Questions
Review Questions
-
1.
In the current nomenclature of the vein of the lower extremity, the acronym GSV refers to:
-
a.
Greater saphenous vein
-
b.
Great saphenous vein
-
c.
Grand saphenous vein
-
d.
Groin saphenous vein
-
a.
-
2.
What is the treatment of choice of superficial thrombophlebitis of the great saphenous vein with thrombus within 3 cm from the saphenofemoral junction?
-
a.
Nonsteroidal anti-inflammatory drugs, leg elevation, and compression stockings
-
b.
Anticoagulation for 3 months
-
c.
Aspirin 81 mg daily
-
d.
High ligation of the great saphenous vein
-
a.
-
3.
What is thought to be the most important basic pathogenic mechanism involved in the development of varicose veins?
-
a.
Venous stasis
-
b.
Venous hypertension
-
c.
Blood flow-driven inflammatory process
-
d.
Thrombosis
-
a.
Answer Key
-
1.
b. In the new nomenclature of the veins of lower limb, the acronym GSV refers to the great saphenous vein, opposed to greater saphenous vein, long saphenous vein, or vena saphena magna.
-
2.
b. The current guidelines for the treatment of thrombophlebitis of the great saphenous vein include low molecular weight heparin at prophylactic dose for 45 days, in addition to nonsteroidal anti-inflammatory drugs, leg elevation, and compression stockings. If thrombus is detected within 3 cm from the saphenofemoral junction, full anticoagulation for 3 months is recommended. Patients with recurrence or contraindications for anticoagulation may be recommended for high ligation of the great saphenous vein.
-
3.
c. It is thought that the development of all the clinical manifestations of chronic venous insufficiency can be ascribed to a blood flow-driven inflammatory process. Leukocytes are activated and marginalized. Adhesion to the endothelium is prompted by the expression of adhesion molecules, such as ICAM-1, VCAM-1, and L and P selectins. Ultimately, they infiltrate the venous wall. Lytic and extracellular matrix enzymes are released (MMP1, MMP2, MMP9) and activated. The extracellular matrix is degraded and the venous wall and valves undergo remodeling [18]. The loss of the venous wall’s most intimal architecture leads to dilation, tortuosity, and the formation of varicose veins.
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Pascarella, L., Shortell, C.K. (2017). Overview of Venous Disorders. In: AbuRahma, A. (eds) Noninvasive Vascular Diagnosis. Springer, Cham. https://doi.org/10.1007/978-3-319-54760-2_38
Download citation
DOI: https://doi.org/10.1007/978-3-319-54760-2_38
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-54758-9
Online ISBN: 978-3-319-54760-2
eBook Packages: MedicineMedicine (R0)